The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 35, No. 7, pp. 943-946. DOI 10.1345/aph.10342
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gianni, L.
Right arrow Articles by Sulli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gianni, L.
Right arrow Articles by Sulli, M.


Research Articles

Topical tacrolimus in the treatment of atopic dermatitis

LM Gianni and MM Sulli

OBJECTIVE: To review the efficacy of topical tacrolimus in the treatment of atopic dermatitis (AD). DATA SOURCES: Searches of MEDLINE (1966-October 2000), International Pharmaceutical Abstracts (1970-October 2000), and ScienceDirect (1994-October 2000) were performed using the key search terms tacrolimus, FK506, and atopic dermatitis. DATA SYNTHESIS: Since patients with AD have defects in cell-mediated immunity, the immunosuppressant properties of the macrolides (cyclosporine and tacrolimus) may prove to be beneficial in the treatment of AD. Topical tacrolimus has been frequently studied in the treatment of AD because it was found to have better skin penetration and higher potentency than topically applied cyclosporine. Studies evaluating the use of topical tacrolimus are presented and provide evidence that topical tacrolimus is effective in the treatment of AD with no evidence thus far of systemic adverse effects. CONCLUSIONS: There is a fair amount of documentation of the efficacy and safety of topical tacrolimus. Further trials are needed to determine the optimal duration of therapy and its efficacy and safety in children less than seven years of age.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
D. Teshima, H. Ikesue, Y. Itoh, K. Urabe, M. Furue, and R. Oishi
Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma
Ann. Pharmacother., October 1, 2003; 37(10): 1444 - 1447.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Mettang, C. Pauli-Magnus, and D. M. Alscher
Uraemic pruritus--new perspectives and insights from recent trials
Nephrol. Dial. Transplant., September 1, 2002; 17(9): 1558 - 1563.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.